|Mr. Eric Weisblum||Chairman, Pres, Chief Compliance Officer, CEO & CFO||115k||N/A||1970|
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research to address conditions, such as depression, post-traumatic stress disorder, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Englewood Cliffs, New Jersey.
Silo Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.